Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

Anaïs Roeser, MD, Marine Bravetti, MD, Levi-Dan Azoulay, MD, Makoto Miyara, MD, Jean-François Emile, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Fleur Cohen-Aubart, MD PhD, Julien Haroche

Blood (2019) 134 (Supplement_1): 2324.

https://doi.org/10.1182/blood-2019-129984

Published: 2019

Journal Articles

Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia

Hanny Al-Samkari, MD, Athena Kritharis, MD, Josanna Rodriguez-Lopez, MD, David J. Kuter, MD DPhil

Blood (2018) 132 (Supplement 1): 852.

https://doi.org/10.1182/blood-2018-99-117144

Published: 2018

Journal Articles

Severe Ocular Graft-Versus-Host Disease Successfully Treated with Amniotic Membrane Transplantation - Case Series

Zinaida Peric, MD PhD, Ivan Skegro, MD, Nadira Durakovic, MD, Lana Desnica, MD PhD, Ranka Serventi-Seiwerth, MD, Drazen Pulanic, MD PhD, Igor Petricek, MD PhD, Steven Z. Pavletic, MD, Radovan Vrhovac, MD PhD

Blood (2017) 130 (Supplement 1): 3270.

https://doi.org/10.1182/blood.V130.Suppl_1.3270.3270

Published: 2017

Journal Articles

The CXCL12/CXCR4 and VEGF165/Nrp1 Pathways Have Differential Effects on Pathological Neo-Angiogenesis and Vascular Remodeling in Hemophilic Arthropathy

Tine L. Wyseure, PhD, Esther J. Cooke, PhD, Annette von Drygalski, MD, Laurent O. Mosnier, PhD

Blood (2017) 130 (Supplement 1): 180.

https://doi.org/10.1182/blood.V130.Suppl_1.180.180

Published: 2017

Journal Articles

Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Acute Myeloid Leukemia Progression and Drug Response

Diana Passaro, PhD, Alessandro Di Tullio, PhD, Ander Abarrategi, PhD, Kevin Rouault-Pierre, PhD, Katie Foster, PhD, Linda Ariza McNaughton, PhD, Francois Lassailly, PhD, Dominique Bonnet, PhD

Blood (2016) 128 (22): 2662.

https://doi.org/10.1182/blood.V128.22.2662.2662

Published: 2016

Journal Articles

Ifnα Mediated Remodeling of the Bone Marrow Stem Cell Vascular Niche

Áine M. Prendergast, PhD, Andrea Kuck, Mieke van Essen, Simon Haas, Sandra Blaszkiewicz, Marieke A. G. Essers

Blood (2016) 128 (22): 2667.

https://doi.org/10.1182/blood.V128.22.2667.2667

Published: 2016

Journal Articles

High Intratumoral Expression of Galectin-1 Correlates with Superior Outcome in HIV-Associated DLBCL

Maja Ludvigsen, MSc PhD, Maja Ølholm Vase, MDPhD, Knud Bendix, Stephen Hamilton-Dutoit, Gabriel A Rabinovich, PhD, Michael Boe Moeller, Court Pedersen, Gitte Pedersen, Niels Obel, Carsten Schade Larsen, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 4142.

https://doi.org/10.1182/blood.V128.22.4142.4142

Published: 2016

Journal Articles

Migration of Acute Lymphoblastic Leukemia Cells into the Central Nervous System Is Regulated By VEGF

Vera Muench, Luca Trentin, PhD, Julia Herzig, Johann Krauss, Hans A Kestler, Geertruy te Kronnie, Klaus-Michael Debatin, MDPhD, Lueder Hinrich Meyer, MD

Blood (2015) 126 (23): 2634.

https://doi.org/10.1182/blood.V126.23.2634.2634

Published: 2015

Journal Articles

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Tait D. Shanafelt, MD, Betsy R. LaPlant, MS, Timothy G Call, MD, Daniel Nikcevich, MD PhD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Adam Pettinger, Daniel L. Van Dyke, PhD, Diane F. Jelinek, Curtis A. Hanson, MD, Neil E. Kay, MD

Blood (2014) 124 (21): 4673.

https://doi.org/10.1182/blood.V124.21.4673.4673

Published: 2014

Journal Articles

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Abdullah Kutlar, MD, Paul S. Swerdlow, MD, Steffen E. Meiler, MD, Kavita Natrajan, MBBS, Leigh G Wells, MSN, RN, FNP-BC, Betsy Clair, Sheetal Shah, BA, Robert Knight, MD

Blood (2013) 122 (21): 777.

https://doi.org/10.1182/blood.V122.21.777.777

Published: 2013

Journal Articles

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Danielle M. Brander, MD, Anne W Beaven, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Thomas C. Shea, MD, Carlos deCastro, Joseph O. Moore, MD, David A. Rizzieri, MD

Blood (2012) 120 (21): 1626.

https://doi.org/10.1182/blood.V120.21.1626.1626

Published: 2012

Journal Articles

ADAMTS13 TSP1 Repeat Domains Promote HUVEC Angiogenesis Via Phosphorylation of VEGFR2.

Manfai Lee, PhD, Juan Xiao, MD, PhD, X. Long Zheng, MD, PhD, Jonathan Baza, BS, Courtney Hoyt, George M Rodgers, MD, PhD

Blood (2012) 120 (21): 2182.

https://doi.org/10.1182/blood.V120.21.2182.2182

Published: 2012

Journal Articles

The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

John F. Seymour, MBBS FRACP, Michael Pfreundshuh, MD, B. Coiffier, MD, Marek Trneny, MD, PhD, Laurie H. Sehn, MD, Eva Csinady

Blood (2012) 120 (21): 58.

https://doi.org/10.1182/blood.V120.21.58.58

Published: 2012

Journal Articles

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Christopher R Cogle, MD, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Maxim Norkin, MD, PhD, David Chaplin, PhD, Jai Balkissoon, MD, Jack W Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, John R Wingard, MD

Blood (2012) 120 (21): 4335.

https://doi.org/10.1182/blood.V120.21.4335.4335

Published: 2012

Journal Articles

Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience

Anita D'Souza, MBBS, MD, Francis K Buadi, M.D., Martha Q Lacy, MD, Morie A Gertz, MD, Suzanne R Hayman, MD, Shaji Kumar, MD, David Dingli, M.D., Ph.D., Steven R Zeldenrust, MD, PhD, Angela Dispenzieri, MD

Blood (2011) 118 (21): 3101.

https://doi.org/10.1182/blood.V118.21.3101.3101

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

Neoangiogenesis contributes to the development of hemophilic synovitis

Suchitra S. Acharya, Rosandra N. Kaplan, Dan Macdonald, Oluwa T. Fabiyi, Donna DiMichele, David Lyden

Blood (2011) 117 (8): 2484–2493.

https://doi.org/10.1182/blood-2010-05-284653

Published: 2011

Journal Articles

Establishment of An HS23 Stromal Cell-Dependent Myeloma Cell Line: Fibronectin and IL-6 Are Critical for Survival

Akira Sakai, MD, PhD, Miyo Oda, PhD, Noriaki Yoshida, MD, Mitsuhiro Itagaki, MD, Koji Arihiro, MD, PhD, Akiro Kimura, MD, PhD

Blood (2010) 116 (21): 2949.

https://doi.org/10.1182/blood.V116.21.2949.2949

Published: 2010

Journal Articles

Inhibition of Endothelial Cell Tube Formation by ADAMTS13 Occurs Via Interaction with VEGF

Eva S. Rodansky, PhD, Justin K. Smith, PhD, Hugh J.L. Fryer, PhD, Robert S. Greenfield, George M. Rodgers, MD, PhD

Blood (2010) 116 (21): 4307.

https://doi.org/10.1182/blood.V116.21.4307.4307

Published: 2010

Journal Articles

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Alison T. Stopeck, MD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Brent Farnsworth, DO, Michael LeBlanc, Ph.D., Maria Iannone, MS, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2010) 116 (21): 591.

https://doi.org/10.1182/blood.V116.21.591.591

Published: 2010

NARROW

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia

Severe Ocular Graft-Versus-Host Disease Successfully Treated with Amniotic Membrane Transplantation - Case Series

The CXCL12/CXCR4 and VEGF165/Nrp1 Pathways Have Differential Effects on Pathological Neo-Angiogenesis and Vascular Remodeling in Hemophilic Arthropathy

Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Acute Myeloid Leukemia Progression and Drug Response

Ifnα Mediated Remodeling of the Bone Marrow Stem Cell Vascular Niche

High Intratumoral Expression of Galectin-1 Correlates with Superior Outcome in HIV-Associated DLBCL

Migration of Acute Lymphoblastic Leukemia Cells into the Central Nervous System Is Regulated By VEGF

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

ADAMTS13 TSP1 Repeat Domains Promote HUVEC Angiogenesis Via Phosphorylation of VEGFR2.

The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Neoangiogenesis contributes to the development of hemophilic synovitis

Establishment of An HS23 Stromal Cell-Dependent Myeloma Cell Line: Fibronectin and IL-6 Are Critical for Survival

Inhibition of Endothelial Cell Tube Formation by ADAMTS13 Occurs Via Interaction with VEGF

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only